Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts
Resistance to Targeted Therapies and the Importance of Retesting Davies
GRACE - Global Resource for Advancing Cancer Education<br />Published on Jun 26, 2018<br /><br />Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GRAC...
Author: cancergrace
Added: 05/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 28, 2019 Category: Cancer & Oncology Source Type: podcasts
How Targeted Therapies Treat Cancer Davies
<br />GRACE - Global Resource for Advancing Cancer Education<br />Published on Jun 26, 2018<br /><br />Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GR...
Author: cancergrace
Added: 05/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 28, 2019 Category: Cancer & Oncology Source Type: podcasts
How it Works - Genetic Testing in Lung Cancer Davies
<br />GRACE - Global Resource for Advancing Cancer Education<br />Published on Jun 26, 2018<br /><br />Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GR...
Author: cancergrace
Added: 05/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 28, 2019 Category: Cancer & Oncology Source Type: podcasts
Cancer Cell Biology 101 Davies
Published on Jun 26, 2018<br /><br />Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GRACE for our Webinar Series on Molecular Diagnostic Testing...
Author: cancergrace
Added: 05/23/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 23, 2019 Category: Cancer & Oncology Source Type: podcasts
FDA Drug Safety Podcast: SFDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
On April 9, 2019 FDA announced we have received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - April 17, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
